| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | ā |
Sells | $0 | 0 | ā |
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as anĀ ā¦
Over the last 12 months, insiders at Immunic, Inc. have bought $0 andĀ sold $0 worth of Immunic, Inc. stock.
On average, over the past 5 years, insiders at Immunic, Inc. have bought $157,466 andĀ sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $16,694 was made by Nash Duane (Executive Chairman) on 2025ā06ā13.
| 2025-06-13 | Nash Duane | Executive Chairman | 20,000 0.0216% | $0.83 | $16,694 | +8.32% | ||
| 2025-06-05 | Neermann Joerg | director | 30,000 0.0308% | $0.76 | $22,800 | +12.16% | ||
| 2025-06-05 | Tardio Jason | President and COO | 12,512 0.0133% | $0.79 | $9,884 | +12.16% | ||
| 2025-06-04 | Neermann Joerg | director | 70,000 0.0726% | $0.77 | $53,900 | +11.61% | ||
| 2025-06-04 | Vitt Daniel | CEO and Director | 15,000 0.0156% | $0.77 | $11,550 | +11.61% | ||
| 2025-06-03 | Rudick Richard Alan | director | 143,075 0.1429% | $0.70 | $100,024 | +17.40% | ||
| 2025-06-03 | Whaley Glenn | Chief Financial Officer | 45,000 0.0458% | $0.71 | $32,076 | +17.40% | ||
| 2024-11-12 | Rudick Richard Alan | director | 87,300 0.0969% | $1.15 | $100,369 | -16.43% | ||
| 2024-02-26 | Vitt Daniel | President and CEO | 14,000 0.0159% | $1.31 | $18,333 | -0.78% | ||
| 2023-05-15 | Whaley Glenn | Chief Financial Officer | 5,000 0.0114% | $1.75 | $8,750 | -22.16% | ||
| 2022-12-14 | Neermann Joerg | director | 47,000 0.1472% | $1.26 | $59,032 | +29.37% | ||
| 2022-12-13 | Neermann Joerg | director | 35,000 0.1105% | $1.25 | $43,610 | +31.45% | ||
| 2022-11-23 | Neermann Joerg | director | 18,000 0.0578% | $1.39 | $25,020 | +19.85% | ||
| 2022-11-22 | Vitt Daniel | President and CEO | 8,000 0.0259% | $1.35 | $10,799 | +24.43% | ||
| 2022-11-07 | Whaley Glenn | Chief Financial Officer | 5,000 0.0164% | $1.50 | $7,475 | +13.99% | ||
| 2022-06-03 | Vitt Daniel | President and CEO | 5,000 0.0151% | $3.10 | $15,500 | -43.22% | ||
| 2022-06-03 | Whaley Glenn | Chief Financial Officer | 3,500 0.0104% | $3.04 | $10,658 | -43.22% | ||
| 2022-05-12 | Muehler Andreas | Chief Medical Officer | 3,500 0.0115% | $5.10 | $17,850 | -59.81% | ||
| 2022-05-12 | Nash Duane | Executive Chairman | 10,000 0.0323% | $5.03 | $50,300 | -59.81% | ||
| 2022-05-12 | Whaley Glenn | Chief Financial Officer | 3,000 0.0098% | $5.08 | $15,240 | -59.81% |
| Muehler Andreas | Chief Medical Officer | 297986 2.1839% | $2.26M | 2 | 0 | <0.0001% |
| Rudick Richard Alan | director | 230375 1.6884% | $1.75M | 2 | 0 | +0.48% |
| Neermann Joerg | director | 200000 1.4658% | $1.52M | 5 | 0 | +20.89% |
| Winters Terence E. | Co-Chairman and CEO | 194966 1.4289% | $1.48M | 2 | 0 | |
| Whaley Glenn | Chief Financial Officer | 95510 0.7% | $725,876.00 | 8 | 0 | <0.0001% |
| SEARS LOWELL | director | 58572 0.4293% | $445,147.20 | 2 | 0 | |
| Nash Duane | Executive Chairman | 36032 0.2641% | $273,843.20 | 6 | 1 | <0.0001% |
| Vitt Daniel | CEO and Director | 29000 0.2125% | $220,400.00 | 5 | 2 | +11.75% |
| BIENAIME JEAN JACQUES | director | 18500 0.1356% | $140,600.00 | 6 | 2 | |
| CROXFORD PHILIP M | director | 17841 0.1308% | $135,591.60 | 1 | 0 | |
| Tardio Jason | President and COO | 12512 0.0917% | $95,091.20 | 1 | 0 | +12.16% |
| DUNN JOHN MICHAEL | General Counsel and Secretary | 11885 0.0871% | $90,326.00 | 3 | 0 | |
| Hasnain Faheem | director | 4500 0.033% | $34,200.00 | 2 | 1 | |
| Ashley Robert A. | Chief Technical Officer, EVP | 2000 0.0147% | $15,200.00 | 1 | 0 | |
| Stern Aron | See Remarks | 1333 0.0098% | $10,130.80 | 1 | 0 | |
| Satter Muneer A | 0 0% | $0 | 22 | 3 | ||
| Godshall Douglas Evan | director | 0 0% | $0 | 2 | 1 | |
| Cohen Cheryl | director | 0 0% | $0 | 1 | 1 | |
| Halperin Errol R. | director | 0 0% | $0 | 2 | 1 |
$5,552,811 | 165 | 5.84% | $106.2M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$130,095 | 43 | 45.19% | $111.24M |
| Increased Positions | 27 | +44.26% | 13M | +29.78% |
| Decreased Positions | 18 | -29.51% | 4M | -9.62% |
| New Positions | 10 | New | 5M | New |
| Sold Out Positions | 9 | Sold Out | 2M | Sold Out |
| Total Postitions | 70 | +14.75% | 51M | +20.17% |
| Aberdeen Group Plc | $4,806.00 | 6.87% | 8.24M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $4,462.00 | 6.38% | 7.65M | 0 | 0% | 2025-09-30 |
| Avidity Partners Management Lp | $2,740.00 | 3.92% | 4.7M | -916,400 | -16.32% | 2025-09-30 |
| Vanguard Group Inc | $2,533.00 | 3.62% | 4.35M | +219,957 | +5.33% | 2025-09-30 |
| Morgan Stanley | $1,809.00 | 2.59% | 3.1M | -525,406 | -14.48% | 2025-09-30 |
| Focus Partners Wealth | $1,505.00 | 2.15% | 2.58M | +39,063 | +1.54% | 2025-09-30 |
| Laurion Capital Management Lp | $1,097.00 | 1.57% | 1.88M | -22,901 | -1.2% | 2025-09-30 |
| Soleus Capital Management, L.P. | $921.00 | 1.32% | 1.58M | -6M | -78.33% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $815.00 | 1.17% | 1.4M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $603.00 | 0.86% | 1.03M | +59,136 | +6.07% | 2025-09-30 |